Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Int J Mol Sci · 2020 · PMC7555161 · PMID 32961800

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A phase III clinical trial reported improved overall survival when L-MTP-PE was combined with systemic adjuvant osteosarcoma therapy for patients with nonmetastatic disease [ 116 ], and another study showed a trend towards improved survival in patients with metastatic disease with this same regime [ 201 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.